Program

6:30 AM-7:45 AM Complimentary Continental Breakfast Provided
6:30 AM-6:30 PM Exhibits
7:00 AM-7:45 AM

Breakout Session: Immunology 101: The Basics

 

Marka R. Crittenden, MD, PhD
Earle A. Chiles Research Institute, Providence Cancer Center

 

Panel Question and Answer

7:45 AM-9:30 AM

Welcome and General Session 1: What Are the Best Immunogenic Targets for Cancer Immunotherapy?

 

Brad Nelson, PhD—Chair
BC Cancer Agency

 

Mary L. (Nora) Disis, MD
University of Washington

Welcome

 

Brad Nelson, PhD
BC Cancer Agency

Session Overview

 

Carl G. Figdor, PhD
Radboud Institute for Molecular Life Sciences

Vaccines Targeting Mutations

 

Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute

Can Immunity Be Generated to “Self” Cancer-Associated Antigens?

 

Olivera J. Finn, PhD
University of Pittsburgh
Shared Antigens as Vaccines for Cancer Prevention 

 

 

Panel Question and Answer

9:30 AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 2: Driving T-Cell Therapies Forward to the Clinic—For Everyone

 

Stephen Gottschalk, MD—Chair
Baylor College of Medicine

CAR T Cells for Solid Tumors: What Are the Challenges?

 

Cameron J. Turtle, MBBS, PhD
Fred Hutchinson Cancer Research Center

CAR T Cells for B-Cell Malignancies

 

Prasad S. Adusumilli, MD
Memorial Sloan Kettering Cancer Center

CAR T Cells for Solid Tumors in Combination with Immune Checkpoint Blockade

 

Ann M. Leen, PhD
Baylor College of Medicine

Multi-tumor-Associated Antigen-Specific T Cells for Therapy

 

Christopher A. Klebanoff, MD
Center for Cell Engineering and Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center

Neoantigen-Specific T-Cell Receptors: From Bench to Bedside

 

Panel Question and Answer

11:45 AM-1:00 PM

Networking Roundtables: Where Does Immunotherapy Fit in Your Practice?

 

Expert faculty willl lead small-group discussions on hematologic malignancies, head and neck cancers, sarcoma, colorectal cancer, brain cancer, and melanoma.

 

For a list of the faculty participants, please visit Networking Opportunities.

11:30 AM-1:00 PM

Poster Session A

With Complimentary Boxed Lunch

1:00 PM-2:15 PM

Oral Abstract Session A

 

Jeffrey Schlom, PhD - Co-Chair

National Cancer Institute Center for Cancer Research

 

John Nemunaitis, MD - Co-Chair

Mary Crowley Cancer Research Centers

 

Abstract 138: The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.

First author: Marie-Andree Forget

 

Discussion: Claire Friedman, MD

Memorial Sloan Kettering Cancer Center

 

Abstract 139: Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC.

First author: Ramon Mohanlal

 

Abstract 140: Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.

First author: Cornelis Melief

 

Discussion: Heather McArthur, MD, MPH

Cedars-Sinai Medical Center

 

Panel Question and Answer

2:15 PM-3:00 PM

Keynote Lecture

 

Ronald N. Germain, MD, PhD
National Institutes of Health

Assessing Anticancer Immune Responses Using Advanced Microscopy Methods

3:00 PM-3:30 PM Break
3:30 PM-5:00 PM

General Session 3: Activating the Immune System—New Clinical Approaches

 

Ezra E.W. Cohen, MD—Chair
University of California, San Diego

 

Brendan D. Curti, MD
Earle A. Chiles Research Institute, Providence Cancer Center

OX40 Monoclonal Antibodies in the Clinic

 

Elizabeth A. Repasky, PhD
Roswell Park Cancer Institute

Thermal Costimulation: Heating Up the Immune System

 

Omid Hamid, MD
The Angeles Clinic and Research Institute

Optimizing Immunity in Melanoma via T-Cell Activation

 

Abstract 77: Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010
First Author: Matthew Hellman

 

Abstract 78: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)
First Author: Alain Algazi

 

Panel Question and Answer

5:00 PM-5:30 PM

Evening Highlights: How Will Today’s Presentations Impact Clinical Practice?

 

Ann W. Silk, MD
Rutgers Cancer Institute of New Jersey

 

Panel Question and Answer

5:30 PM-6:30 PM

Poster Session A (Continued) and Networking Reception

With Complimentary Wine and Cheese

5:45 PM-6:30 PM

Poster Walks

 

Julie Djeu, PhD

H. Lee Moffitt Cancer Center & Research Institute

 

Kavita Dhodapkar, MD

Yale University